Results. Among the 44 participants, mean age is 40 years; 73% are males; 48% Hispanic, 38% non-Hispanic white; 7% non-Hispanic black and 7% mixed-race or other. Almost all (96%) had health insurance, with 86% having public insurance (Medicaid). Most participants (91%) were aware of their HCV diagnosis before enrollment. All wanted to be treated for HCV, and 88% wanted treatment to prevent infecting others. 48% had previously been referred for HCV treatment, only 21% had been offered treatment, and none had started. When asked about barriers to treatment, 56% participants felt that they would need to stop using drugs to get HCV treatment, 61% felt that HCV treatment had many side effects and 20% reported insurance coverage barriers.
Background. Hepatitis C virus (HCV) infection has received significant attention in recent years due to the ability for near universal cure, the price of therapy, and increasing incidence due to injection drug use. While the discussion largely focuses on HCV infection in adults, children with HCV are a consistent minority of patients with long-term adverse outcomes of HCV. Few studies have defined the healthcare utilization of HCV-infected children.
Objective: To define trends in pediatric HCV cases and healthcare utilization using a national administrative database.
Methods. The Pediatric Health Information Systems (PHIS) database contains inpatient encounter-level data from tertiary care pediatric hospitals in the United States. We identified pediatric HCV cases using validated ICD-9/ICD-10 diagnosis codes (070.41, 070.44, 070.51, 070.54, 070.70, 070.71, V0262, B18.2) . We evaluated total cases identified, year of presentation, patient age, geographic location by state, aggregate cost of providing care and HIV-coinfection (ICD-9 code 042/ICD-10 code B20).
Results. Since 1992, there were 2,175 unique pediatric patients identified with HCV infection. Case rates were highest in patients 15-17 years with a peak of 24 cases/10,000 admissions that fell to 10 cases /10,000 in 2,000 and a low of 1 case/10,000 in 2015. Alarmingly, the rate in this group was back over two cases/10,000 in 2016 and 2017. HCV case rates in children 11-14 were the second highest with more sustained peak from 1992 to 2006 and no precipitous decline. There were 49 patients with HIV co-infection, with rates highest prior to 1998 (range of 6.5-18%), but since 2002 have been <2% until 2017 (2.5%). For inpatient costs, 10% of HCV infected children accounted for 75% of the total cost of care. In 2004-2006, total charges for 329 HCV-infected children were just over $23 million, compared with 2015-2017 when total charges for 247 HCV-infected children were $21.8 million. Comparing these two eras and adjusting for inflation, there was a 3% decline in charges per patient.
Conclusion. While the burden of inpatient HCV in children has declined since the peak in the early 1990s, there are worrisome increases detected in the last few years. A small minority of patients represent a disproportional amount of the total care provided. Early treatment of children would still likely prove cost-effective. Saturday, October 6, 2018: 12:30 PM Background. The rise in injection drug use in the rural United States has led to an increase in admissions for injection-related conditions. Hepatitis C (HCV) infection is prevalent amongst people who inject drugs and might be diagnosed during such episodes of acute care. Linkage to care and initiation of treatment for hepatitis C in this group has been difficult, especially in rural settings lacking comprehensive care for people with substance use disorder (SUD).
Methods. We reviewed the charts of patients admitted to an inpatient service at Dartmouth-Hitchcock Medical Center (DHMC) who had positive HCV serology in 2016. We determined the proportion of patients who had follow-up testing for HCV RNA, were referred, followed up and initiated treatment for HCV by the end of 2017.
Results. In 2016, 504 inpatients at DHMC were screened with an HCV antibody test, of which 65 (13%) were positive. Of these, 50 (77%) had follow-up HCV RNA testing, resulting in 38 (76%) patients with detectable viremia. Of the 53 patients with detected (38) or unknown viremia (15), five died on the index admission, one was discharged to a hospice, 16 were referred to the DHMC hepatology (GI) clinic and 11 to the DHMC infectious disease (ID) clinic, but 20 received no referral. Thirty-two (60%) patients had an active SUD, and 7 (13%) were in remission.
Through December 31, 2017, 15 (31%) of the surviving 48 patients had no further follow-up in the Dartmouth-Hitchcock Health System. Fourteen (29%) patients followed up in the GI clinic, 11 (23%) followed up in the ID clinic and 8 (17%) had subsequent encounters in clinics for conditions other than HCV. Only 5 (10%) patients were treated for HCV and achieved sustained virologic response (SVR), all of which had followed up in the GI clinic. The odds of follow-up or treatment were independent of a history of SUD. Providers frequently deferred treatment due to ongoing substance use or a focus on more urgent medical issues. Insurance coverage for direct-acting antivirals was evolving during the study period, preventing treatment in some patients.
Conclusion. Only 10% of patients screened positive for HCV during an inpatient admission to a rural academic medical center received treatment for HCV in the year following their diagnosis. Linkage to care, patient engagement and provider perceptions have to improve to achieve elimination of HCV.
Disclosures. All authors: No reported disclosures. Background. Knowledge about HCV treatment uptake, regimens and providers in the era of all-oral directly acting antiviral agents is critical for patients, providers, payers and policy makers. Our objective was to determine the number of persons initiated on HCV treatment over time, and trends in providers who initiate treatment Methods. Among all HCV+ persons in ERCHIVES from 2001 to 2017, we identified all persons who initiated HCV treatment and medical specialty of the provider initiating treatment. Results were tabulated by VA fiscal year.
Treatment Uptake for Hepatitis C Virus Infection in the Veterans
Results. A total of 108,133 persons were initiated on treatment (Figure 1 ). Sofosbuvir-based regimens were the most commonly used regimens, accounting for nearly two-thirds of all DAA regimens. Gastroenterologists/hepatologist were the most common initiators of treatment in the pre-DAA era accounting for 26. Conclusion. There has been a dramatic increase in HCV treatment uptake in the VA healthcare system with the approval of newer all-oral DAA regimens. Treatment paradigm appears to be shifting toward lesser gastroenterologists/hepatologists and more allied health professionals treating HCV. Saturday, October 6, 2018: 12:30 PM Background. Hepatitis C virus (HCV) infection disproportionately affects HIVinfected patients. HIV/HCV Co-infected patients are more likely to develop advanced liver disease/cirrhosis in comparison to mono-infected patients. HCV treatment with new oral direct-acting antiviral (DAA) therapy is effective in HIV/HCV co-infected patients with cure rate similar to mono-infected patients. Despite the effective treatments, only small portion of co-infected patients are treated for HCV infection. One of the known barriers to HCV treatment is active substance abuse. However, there is limited information about outcomes of HCV treatment with active substance abuse in HIV/HCV co-infected patients. Our primary aim was to evaluate Hepatitis C treatment outcomes in HIV/HCV co-infected patients with active substance abuse (ASA).
Wirelessly Observed Therapy with a Digital Medicines Program to Optimize Adherence and Target Interventions for Oral Hepatitis C Treatment
Methods. We performed a retrospective cross-sectional study of HIV/HCV co-infected patients that were treated for HCV between 2014 and 2017 at Drexel University, Philadelphia, PA. We defined active substance abuse (ASA) by self-report of active drug use at the time of treatment evaluation. We described patient demographics and overall HCV sustained virologic response at 12 weeks after treatment.
Results. One hundred thirty-eight HIV/HCV co-infected patients were treated. The majority (N = 134, 97%) achieved sustained virologic response (SVR) after 12 weeks of treatment. Thirteen patients were active substance abusers, nine used cocaine, three used intravenous drug, and one used both. Twelve (92%) patients in the ASA group achieved SVR at 12 weeks in comparison to 122 (98%) in the non-ASA group (P = 0.26). ASA group had a higher rate of psychiatry comorbidities in comparison to the none-ASA group (100% vs. 58%, P = 0.002).
Conclusion. In our study, direct active antiviral HCV treatment was highly effective in HIV/HCV co-infected patients. Treatment outcomes were not different between active substance abuse group and none user group. Given co-infected patients have worsened prognosis with chronic HCV infection, active substance abuse should not be an absolute contraindication to HCV treatment.
Disclosures. Saturday, October 6, 2018: 12:30 PM Background. Hepatitis C virus (HCV) infection is one of the leading causes of mortality and morbidity in the United States with an incidence of about 0.7 cases per 100,000 population and a prevalence of ~2.7 to 3.9 million people. To our knowledge only one study was performed so far to assess the relation between treating hepatitis C virus using direct acting antiviral drugs (DAA) and reduction in the severity of type 2 diabetes mellitus (DM). Our study aims to assess the effect of SVR in hepatitis C virus on type 2 DM. The effect of the management with newer agents leading to sustained virologic response (SVR) on type 2 DM was analyzed in hepatitis C virus infection.
Methods. We performed a retrospective chart review in our hepatitis clinic located in Shreveport, Louisiana. Patients with age greater than 18 years old, who has both uncontrolled hepatitis C and type 2 DM, seen in our clinic from November 1, 2014 to December 31, 2017 were included. Hospital electronic health records were screened for diagnosis of hepatitis C and uncontrolled type 2 DM by ICD codes. We performed paired sample t-test between pre-and 6-month post-treatment-values of fasting blood sugar and Body Mass Index (BMI).
Results. There was a statistically significant improvement in fasting blood sugar levels following hepatitis C therapy from 184.2 ± 74.8 to 133.06 ± 48.2 (P < 0.01), with an improvement of 51.2 ± 77.6 respectively (N = 49).There was a statistically significant improvement in HbA1c levels following hepatitis C therapy from 8.062 ± 1.8 to 7.019 ± 0.96 (P < 0.05), with an improvement of 1.042 ± 2.03 respectively (N = 21).There was no statistically significant improvement in BMI levels following hepatitis C therapy from 29.91 ± 6.6 to 29.79 ± 6.7 (P > 0.05), with slight improvement of 0.11 ± 2.08 respectively (N = 49).
Conclusion. We conclude that there was statistical significant reduction in fasting blood sugar and hemoglobin A1C levels after achieving sustained virological response with new direct antiviral treatment for hepatitis C. A pre-and posttreatment change in body mass index was statistically not significant implies that change in blood sugar level was not due to weight loss. There was no change in diabetic medication during the period of the study or there were no dose adjustments occurred.
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